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Abstract 
 
The percutaneous driveline used in contemporary LVADs presents a continuous 
risk of infection for the duration of support. Minimizing infection in durable 
mechanical circulatory support systems requires total implantation of all 
components and energy transfer by means other than percutaneous drivelines. A 
novel coplanar energy transfer (CET) system, similar to the original 
transcutaneous energy transfer (TET) design, is unique by incorporating two large 
rings with coil-within-the-coil topology to ensure strong resonance power. The CET 
system consists of an internal integrated controller, a battery coupled with an 
internal thoracic coil ring, and the LVAD pump. External equipment includes a 
power transmission belt with an external controller, a battery, and wristwatch 
monitor. The CET system is adaptable to multiple LVAD designs, though the Jarvik 
2000 (Jarvik Heart, Inc., New York, NY) with postauricular power cable was used 
in the initial clinical cases. Two male patients, ages 51 years and 24 years, 
underwent implantation of the CET/Jarvik 2000 system for the bridge to transplant 
indication. One patient experienced a stroke and device thrombosis which led to 
termination of LVAD support while the patient waited for transplantation. The 
second patient underwent successful transplant after two months of support. The 
CET functioned as intended in both patients. Larger, multicenter, controlled clinical 
trials are necessary to determine the long-term safety and efficacy of the CET 
technology. 
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Introduction 
 
Infection following left ventricular assist device (LVAD) implantation is a leading 
cause of morbidity, mortality, hospital readmission, and high cost of care.1,2 The 
required percutaneous driveline for contemporary LVADs presents a continuous 
risk of infection for the duration of support. Minimizing infection in durable 
mechanical circulatory support systems requires total implantation of all 
components and energy transfer by means other than percutaneous drivelines. 
Elimination of the percutaneous driveline by integration of transcutaneous energy 
transfer (TET) has been performed successfully in earlier designs of the LVAD and 
total artificial heart,3,4 but is not currently incorporated into the widely used LVAD 
systems today. 
 
A novel coplanar energy transfer (CET) system, similar to the original TET design, 
is unique by incorporating two large rings with coil-within-the-coil topology to 
ensure strong resonance power. The CET system (Leviticus Cardio, Ltd., Petach 
Tikva, Israel) is designed for total implantation of an LVAD with wireless power and 
control with no percutaneous driveline. The system is designed to be adaptable for 
use in multiple blood pump systems. An internal battery can provide greater than 8 
hours of continuous untethered operation. The initial clinical implants have been 
performed at the National Research Cardiac Surgery Center, Astana, 
Kazakhstan.5 In this report, we provide a description of the CET system and the 
clinical status of the first patients implanted with the system. 
 
 
Methods 
 
CET system description 
The CET system consists of an internal integrated controller, a battery coupled 
with an internal thoracic coil ring, and the LVAD pump (Figure 1A). External 
equipment includes a power transmission belt with an external controller, a battery, 
and wristwatch monitor (Figure 1B). The integrated controller and battery are 
coupled with an internal thoracic coil ring. The CET system allows a greater 
distance between transmitter and receiver coils and can reach power levels of up 
to 30 Watts with 75% efficiency. The coil ring is placed around the lung and fixed 
to the chest wall. Power is received by the coil ring from the external power 
transmission belt. The internal controller and battery control the power circuits, 
activate the LVAD’s brushless DC motor, communicate with the external controller, 
and control the battery charging circuits. The battery provides power backup and 
enables several hours of operation without the external transmission belt. The user 
watch provides status and alarm information for the patient. The power 
transmission belt transmits power to the internal receiver coil by magnetic 
coupling. The external controller runs the power transmission control algorithm, 
communicates with the pump, and pushes power to the belt, using special power 
driver circuits. The external battery provides the main power source to the 
implanted pump. A tablet is used mainly for patient-specific configuration during 
device startup. 
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Figure 1. The CET system internal components (A): Jarvik 2000 pump with 
postauricular power cable, coil ring, and controller/battery and external 
components (B): power transmission belt, controller and battery, and user 
wristwatch. 
 
 
The CET system is adaptable to multiple LVAD designs, though the Jarvik 2000 
(Jarvik Heart, Inc., New York, NY) with postauricular power cable was used in the 
initial clinical cases.6 For safety in the initial clinical tests, employment of the Jarvik 
2000 system with a retroauricular pedestal that connects to an external power 
source may be used as a backup in case of component failure of the CET system. 
The original Jarvik 2000 controller, battery, and monitor are replaced by the CET 
system controller.  
 
Implantation 
Implantation is accomplished through a median sternotomy approach. The power 
cable is tunneled from the thorax to the base of the skull, where it is attached to 
the skull pedestal. The lung is deflated, and the coil size is determined by sizers. 
The coil is positioned horizontally around the circumference of the lower portion of 
a pleural cavity. A pocket for the controller-battery is created between the serratus 
and latissimus dorsi muscles, along the lateral thoracic. Cardiopulmonary bypass 
is started, the pump is implanted into the left ventricle, and a parallel V-shaped 
driveline from the pump and internal coil are tunneled through an intercostal space 
to the controller. Both connectors are secured, the pump is started, and 
cardiopulmonary bypass is weaned. 
 
Patients 
Two male patients, ages 51 years (Patient A) and 24 years (Patient B), underwent 
implantation of the CET/Jarvik 2000 system for the bridge to transplant indication 
(Table 1). Both patients had NYHA class IV heart failure symptoms and were 
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classified as INTERMACS profile 3. Patient A experienced an ischemic stroke 
(modified Rankin Scale score >3) and required prolonged intensive care and 
rehabilitation. Computed tomography revealed pump thrombosis and occlusion of 
the outflow, consistent with high power requirements from the CET. A 
multidisciplinary team decided to terminate the LVAD and CET operation, and the 
patient was started on intravenous inotropic support. The patient remained stable 
with adequate organ function and was on the heart transplant waiting list. 
Implantation and recovery for Patient B was uneventful, and he was discharged 
from the hospital 30 days after implantation. After 3 days in the intensive care unit, 
Patient B became ambulatory and was without complications. He underwent 
successful heart transplant after 2 months of support. During outpatient support, 
the patient participated in common activities, including walking, shopping, and 
swimming.  
 
Table 1. Patient Characteristics 
 Patient A Patient B 
Age (years) 51 24 
Gender Male Male 
Body surface area (m2) 2.02 1.89 
Etiology Ischemic Non-ischemic 
Left ventricular ejection fraction 
(%) 
11 22 
Cardiac index (L/m2) 1.9 2.2 
Pulmonary wedge pressure 
(mmHg) 
24 20 
Central venous pressure 6 5 
NYHA class IV IV 
INTERMACS profile 3 3 
 
 
System performance 
There were no malfunctions of the CET/Jarvik 2000 LVAD system. The CET 
system functioned as designed in both patients. Untethered operation was 
accomplished for 8.5 hours before the first alert for battery recharge. These alerts 
occur when 1 hour of power remains. Critical alarms occur at low battery levels for 
immediate recharge of the internal battery. 
 
 
Discussion 
 
These initial cases using the CET/Jarvik 2000 LVAD system demonstrate the 
feasibility of durable LVAD support without the need for a percutaneous driveline. 
This represents an important advancement for long-term mechanical circulatory 
support, as the continuous risk of device-related infections may be greatly 
reduced. Device-related infection, and in particular percutaneous driveline 
infection, is a long-standing problem that significantly contributes to morbidity and 
mortality.7-9 Elimination of the percutaneous driveline from durable mechanical 
circulatory support systems may enhance survival with less morbidity and overall 
cost of care in the future. 
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Concern for safety in a totally implanted LVAD system is paramount. In these initial 
studies, an externalized postauricular connector was employed as a backup in 
case of any failure of the CET system⎯it was not utilized in these cases. Also, the 
selected patients were transplant candidates, which offered a secondary bailout, if 
needed. The CET system did not reveal any negative effects on lung function, and 
chest x-rays and CT scans did not show signs of atelectasis or compression of the 
lung. The long-term effects of the CET implant on pulmonary function remains 
unknown. 
 
The CET system was developed with the intent to be integrated with most durable 
mechanical circulatory support systems. Long-term animal studies have 
demonstrated feasibility for CET use with other available devices.5 Larger, 
multicenter, controlled clinical trials are necessary to determine the long-term 
safety and efficacy of the CET technology. At the time of this writing, no additional 
implants have been performed pending further technology and regulatory 
developments. 
 
 
Discussion 
The authors would like to acknowledge Tim Myers for editorial assistance and 
special thanks to Leviticus-Cardio, Ltd for their permission to use the images seen 
in Figure 1. 
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